How Centralized Fulfillment is Making Pharmacy More Efficient
Drug Topics
NOVEMBER 25, 2024
Tom Utech, PharmD, CEO of iA, joined Drug Topics to discuss his company’s centralized pharmacy fulfillment solutions.
Mon.Nov 25, 2024
247 
FDA Approves Oral Liquid Solution of Imatinib for Certain Forms of Leukemia and Other Cancers
Pharmacy Times
NOVEMBER 25, 2024
This is the first oral liquid form of imatinib (Imkeldi; Shorla Oncology) to be approved to treat cancers.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Q&A: How a Community Pharmacist is Helping Other Pharmacies Through Consulting
Drug Topics
NOVEMBER 25, 2024
Benjamin Jolley, PharmD, pharmacist at Jolley’s Compounding Pharmacy in Salt Lake City, Utah, joined Drug Topics to discuss his career journey.
Study Results Show 1 in 20 Adults With RSV Are Hospitalized
Pharmacy Times
NOVEMBER 25, 2024
Findings highlight the unmet medical need for outpatient interventions and preventive measures that can reduce hospitalizations.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Review: Lebrikizumab-lbkz Demonstrates Improvement in Atopic Dermatitis
Drug Topics
NOVEMBER 25, 2024
FDA approval was granted on September 13, 2024.
AI and automation to drive “substantial progress” in pharmaceutical analytical testing
European Pharmaceutical Review
NOVEMBER 25, 2024
The pharmaceutical analytical testing market is seeing significant growth following a greater incidence in the complexity of medicine development and higher demand for biologics and biosimilars, according to a report by Straits Research Pvt. Ltd. Their analysis projected that the market will exceed a value of $15.46 billion by 2032. The market is furthermore expected to see a compound annual growth rate (CAGR) of 7.3 percent between 2024 and 2032.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Does Entresto lower blood pressure?
The Checkup by Singlecare
NOVEMBER 25, 2024
Entresto tablets contain two drugs: valsartan and sacubitril. This combination allows your heart to pump blood more efficiently, managing certain types of heart failure in adults and children older than 1, and helping to lower the risk of death and hospitalization. Entresto belongs to a class of drugs called angiotensin receptor neprilysin inhibitors ( ARNIs ).
FDA Approves Acoramidis for ATTR-CM
Drug Topics
NOVEMBER 25, 2024
This approval marks the availability of the first near-complete stabilizer of transthyretin.
UnitedHealthcare wins 2025 star ratings lawsuit requiring CMS to recalculate results
Fierce Healthcare
NOVEMBER 25, 2024
UnitedHealthcare successfully won its lawsuit over the Centers for Medicare and Medicaid Services, a federal judge determined Nov. 22. | UnitedHealthcare will get to claim victory over CMS for its star ratings lawsuit win. The insurer will receive a recalculated score from the federal agency, potentially giving the insurer more in quality bonus payments.
ASH: Incyte's Monjuvi triumphs in follicular lymphoma phase 3, teeing up FDA filing
Fierce Pharma
NOVEMBER 25, 2024
Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol Myers Squibb's Revlimid and Roche's Rituxan—triggered a 57% reduction in the risk of disease progression, relapse or death in R/R FL patients compared with those who were treated with placebo, Revlimid and Rituxan.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
OCR missed opportunities to prevent health information breaches: HHS watchdog
Fierce Healthcare
NOVEMBER 25, 2024
HHS' Office of the Inspector General released a report on Monday that badgers the Office for Civil Rights' enforcement of HIPAA.
Community Health Care Workers Connect Children With Asthma to Care in Trigger Environments
Pharmacy Times
NOVEMBER 25, 2024
Community health care workers help support both primary care and school settings by assisting with medication administration and communications with staff.
Relief for AZ as Truqap hits the spot in prostate cancer
pharmaphorum
NOVEMBER 25, 2024
After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer.
Bristol Myers Squibb hands pink slips to 195 workers in NJ as cost-cutting effort rolls on
Fierce Pharma
NOVEMBER 25, 2024
Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. | Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. The company has handed pink slips to 195 more employees, according to a New Jersey Worker Adjustment and Retraining Notification (WARN) update.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations
Pharmacy Times
NOVEMBER 25, 2024
Once relatively obscure, PBMs are now front and center in debates over drug pricing and access. Their future role will have profound implications not only for how medications are priced but also for how pharmacies conduct their operations.
Halozyme abandons its €2bn pursuit of Evotec
pharmaphorum
NOVEMBER 25, 2024
Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations.
Acoramidis Received FDA Approval for Treatment of Transthyretin Amyloid Cardiomyopathy
Pharmacy Times
NOVEMBER 25, 2024
Acoramidis is a novel, highly potent transthyretin stabilizer.
BridgeBio poised to challenge Pfizer after Attruby approval
pharmaphorum
NOVEMBER 25, 2024
BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Disappearance of B/Yamagata Strain Influences Flu Vaccine, Public Health Decisions
Pharmacy Times
NOVEMBER 25, 2024
The disappearance could impact updates for surveillance strategies and vaccine development.
UK digital health funding should be ringfenced, says report
pharmaphorum
NOVEMBER 25, 2024
IT industry group techUK has called on the government to guarantee funding for digital transformation and cyber resilience in health and social care.
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices
Pharmacy Times
NOVEMBER 25, 2024
An ACCP speaker explains that the FDA faces a multitude of challenges.
Amid cost debate, new study finds 137M US adults are eligible for GLP-1s
Fierce Healthcare
NOVEMBER 25, 2024
Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would benefit from the drugs. | Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would benefit from the drugs.
Current Landscape of Bispecific Therapies for RRMM
Pharmacy Times
NOVEMBER 25, 2024
Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple
Health Innovators: Lori Fletcher and Amber Beimer, Advanced Clinical
pharmaphorum
NOVEMBER 25, 2024
Watch this exclusive interview with health innovators Lori Fletcher and Amber Beimer from Advanced Clinical as they discuss the latest trends and advancements in the Functional Service Provider (FSP) field.
Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing
Pharmacy Times
NOVEMBER 25, 2024
Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.
GSK gains approval in Japan for extended indication of RSV vaccine
Pharmaceutical Technology
NOVEMBER 25, 2024
GSK has received approval from Japan's MHLW for its application to extend the indication of its RSV vaccine, Arexvy.
STRIPE Annual Meeting: Standardizing Clinical Utility in Pharmacogenetics
Pharmacy Times
NOVEMBER 25, 2024
Jai N. Patel, PharmD, BCOP, CPP, discussed efforts to standardize the evaluation of clinical utility in pharmacogenetics, emphasizing its variability, the role of pharmacogenomics in research, and the importance of robust study designs for pharmacy professionals.
Autism provider Cortica gets $80M in strategic round to expand VBC contracts, footprint
Fierce Healthcare
NOVEMBER 25, 2024
Morgan Health, a business unit of JPMorgan Chase, has co-led an $80 million raise for Cortica, a provider for autistic and neurodivergent children. | The strategic round follows Cortica’s series D and was co-led by Morgan Health, a business unit of JPMorgan Chase, and Nexus NeuroTech Ventures, with participation from Autism Impact Fund.
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
Pharmacy Times
NOVEMBER 25, 2024
Expert discussed benefits of precision oncology treatments that utilize thousands of biomarkers to design personalized treatment plans.
Mikkel Wandahl Pedersen
Pharma Times
NOVEMBER 25, 2024
Commit Biologics has appointed Mikkel Wandahl Pedersen as CSO
CPhOs issue advice to pharmacy professions on assisted dying debate
Hospital Pharmacy Europe
NOVEMBER 25, 2024
The UK’s most senior pharmacists have issued advice to those among the pharmacy professions who want to take part in the public debate around assisted dying. Chief pharmaceutical officers (CPhOs) for the four home nations and other pharmacy leaders have said it is ‘entirely reasonable’ for pharmacists and pharmacist technicians to give their opinions and that ‘the public would expect that’.
Peer Exchange: RFID Technological Obstacles (Episode 2)
Pharmaceutical Commerce
NOVEMBER 25, 2024
In the second part of this roundtable discussion, key opinion leaders discuss the potential technological challenges surrounding RFID, and the likelihood of not only utilizing this tech at the item level but for product security purposes as well.
Adcendo raises $135m as ADC funding frenzy continues
Pharmaceutical Technology
NOVEMBER 25, 2024
This latest raise is intended to accelerate the development of the biotech’s four antibody-drug conjugates.
Let's personalize your content